{"nctId":"NCT01014013","briefTitle":"Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)","startDateStruct":{"date":"2008-04"},"conditions":["Urinary Tract Infection"],"count":271,"armGroups":[{"label":"ertapenem sodium (MK0826)","type":"EXPERIMENTAL","interventionNames":["Drug: ertapenem sodium (MK0826)"]},{"label":"ceftriaxone sodium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: ceftriaxone sodium"]}],"interventions":[{"name":"ertapenem sodium (MK0826)","otherNames":["MK0826"]},{"name":"Comparator: ceftriaxone sodium","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients with a suspected or documented complicated urinary tract infection\n* Female patients must test negative for pregnancy and agree to use adequate birth control measures\n* Nursing women must agree to defer breastfeeding until 5 days after completion of all study antibiotic therapy\n\nExclusion Criteria:\n\n* Patients with complete obstruction of any portion of the urinary tract\n* Patients with rapidly progressive or terminal illness\n* Renal transplant patients","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Microbiological Response Assessment Profile","description":"The difference in favorable microbiological response rates between the 2 treatment groups (MK0826 response rate minus ceftriaxone response rate) was assessed","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Patients Who Experience Any Drug-related Adverse Experiences Leading to Discontinuation of Parenteral Study Drug and the Number of Patients With Any Drug-related Serious Adverse Experiences (AEs) During Parenteral Treatment","description":"Safety was assessed by statistical and/or clinical review of all safety parameters, including adverse experiences, physical examination, vital signs, and laboratory results during parenteral therapy. As per the primary safety hypothesis, it was expected that, at the end of the parenteral therapy only, MK0826 would be similar to ceftriaxone with respect to the proportion of patients with any drug-related clinical or laboratory adverse experiences leading to discontinuation of study drug and also with respect to the proportion of patients with any serious drug-related adverse experiences.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response Assessment Profile","description":"The difference in favorable clinical response rates between the 2 treatment groups (MK0826 response rate minus ceftriaxone response rate) was assessed","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":132},"commonTop":["Diarrhea","Headache","Dyspepsia","Cough","Constipation"]}}}